1
|
Yang J, Liao X, Hu D, Mo J, Gao X, Liao H. Study on the design, synthesis, and activity of anti-tumor staple peptides targeting MDM2/MDMX. Front Chem 2024; 12:1403473. [PMID: 38911993 PMCID: PMC11190158 DOI: 10.3389/fchem.2024.1403473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Accepted: 05/20/2024] [Indexed: 06/25/2024] Open
Abstract
Staple peptides, which have a significantly enhanced pharmacological profile, are promising therapeutic molecules due to their remarkable resistance to proteolysis and cell-penetrating properties. In this study, we designed and synthesized a series of PMI-M3-based dual-targeting MDM2/MDMX staple peptides and compared them with straight-chain peptides. The staple peptide SM3-4 screened in the study induced apoptosis of tumor cells in vitro at low μM concentrations, and the helix was significantly increased. Studies have shown that the enhancement of staple activity is related to the increase in helicity, and SM3-4 provides an effective research basis for dual-targeted anti-tumor staple peptides.
Collapse
Affiliation(s)
- Jian Yang
- The Third Affiliated Hospital of Chengdu Medical College (Chengdu Pidu District People’s Hospital), Chengdu, China
| | | | - Damin Hu
- School of Medicine, Tarim University, China
| | - Jinqiu Mo
- School of Medicine, Tarim University, China
| | - Xiurong Gao
- School of Pharmacy, Chengdu Medical College, Chengdu, China
| | - Hongli Liao
- School of Pharmacy, Chengdu Medical College, Chengdu, China
| |
Collapse
|
2
|
Thomas QD, Boussere A, Classe JM, Pomel C, Costaz H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, Rouge TDLM, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecol Oncol 2022; 167:11-21. [PMID: 35970603 DOI: 10.1016/j.ygyno.2022.08.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Revised: 07/30/2022] [Accepted: 08/07/2022] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Interval debulking surgery is recommended after 3-4 cycles (standard IDS) of neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after ≥5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS. METHODS We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were compared using Cox model with adjustments for confounding factors provided by two propensity score methods: inverse probability of treatment weighting (IPTW) and matched-pair analysis. RESULTS 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22-1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06-1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65-0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68-1,03]; p = 0.0947). CONCLUSIONS Carrying IDS after ≥5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3-4 NACT cycles.
Collapse
Affiliation(s)
- Quentin Dominique Thomas
- Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.
| | - Amal Boussere
- Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France
| | - Jean-Marc Classe
- Department of Surgical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint Herblain, France
| | - Christophe Pomel
- Department of Surgical Oncology, Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR INSERM-UCA, Clermont-Ferrand, France
| | - Hélène Costaz
- Department of Surgical Oncology, Centre Georges-François Leclerc, Dijon, France
| | | | | | - Laurence Gladieff
- Department of Medical Oncology, Institut Claudius Régaud IUCT-O, Toulouse, France
| | - Roman Rouzier
- Department of Surgical Oncology, Centre François Baclesse, Caen, France
| | | | - Sébastien Gouy
- Department of Surgery, Gustave Roussy, Villejuif, France
| | | | - Renaud Sabatier
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Anne Floquet
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - Frédéric Marchal
- Departement of Surgery, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
| | - Cécile Guillemet
- Department of Medical Oncology, Centre Henri Becquerel, Rouen, France
| | - Valentine Polivka
- Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France
| | | | - Pierre-Emmanuel Colombo
- Departement of Surgery, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France
| | - Frédéric Fiteni
- Departement of Medical Oncology, University Hospital of Nîmes, University of Montpellier, UMR UA11 INSERM, IDESP Institut Desbrest d'Epidémiologie et de Santé Publique, Montpellier, France
| |
Collapse
|